EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nucleotide-Binding Oligomerization Domain 1 (NOD1) Agonists Prevent SARS-CoV-2 Infection in Human Lung Epithelial Cells through Harnessing the Innate Immune Response

Edurne Garcia-Vidal, Ignasi Calba, Eva Riveira-Muñoz, Elisabet García, Bonaventura Clotet, Pere Serra-Mitjà iD, Cecilia Cabrera, Ester Ballana iD, Roger Badia

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25105318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Edurne Garcia-Vidal und 8 weiteren Autor:innen. Beteiligte Einrichtung: IrsiCaixa, 08916 Badalona, Barcelona, Spain. Hauptthemen laut MEDLINE: COVID-19, Epithelial Cells, Lung, Nod1 Signaling Adaptor Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Departament de Salut, Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The lung is prone to infections from respiratory viruses such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). A challenge in combating these infections is the difficulty in targeting antiviral activity directly at the lung mucosal tract. Boosting the capability of the respiratory mucosa to trigger a potent immune response at the onset of infection could serve as a potential strategy for managing respiratory infections. This study focused on screening immunomodulators to enhance innate immune response in lung epithelial and immune cell models. Through testing various subfamilies and pathways of pattern recognition receptors (PRRs), the nucleotide-binding and oligomerization domain (NOD)-like receptor (NLR) family was found to selectively activate innate immunity in lung epithelial cells. Activation of NOD1 and dual NOD1/2 by the agonists TriDAP and M-TriDAP, respectively, increased the number of IL-8+ cells by engaging the NF-κB and interferon response pathways. Lung epithelial cells showed a stronger response to NOD1 and dual NOD1/2 agonists compared to control. Interestingly, a less-pronounced response to NOD1 agonists was noted in PBMCs, indicating a tissue-specific effect of NOD1 in lung epithelial cells without inducing widespread systemic activation. The specificity of the NOD agonist pathway was confirmed through gene silencing of NOD1 (siRNA) and selective NOD1 and dual NOD1/2 inhibitors in lung epithelial cells. Ultimately, activation induced by NOD1 and dual NOD1/2 agonists created an antiviral environment that hindered SARS-CoV-2 replication in vitro in lung epithelial cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Epithelial CellsLungNod1 Signaling Adaptor ProteinSARS-CoV-2HumansA549 CellsAntiviral AgentsCOVID-19 Drug TreatmentDiaminopimelic AcidImmunity, InnateInterleukin-8NF-kappa BNod2 Signaling Adaptor ProteinSignal Transduction

Stichwörter der Autor:innen

NOD-like receptorSARS-CoV-2innate immunityrespiratory mucosaviral respiratory infections

Substanzen

Antiviral AgentsDiaminopimelic AcidInterleukin-8NF-kappa BNOD1 protein, humanNod1 Signaling Adaptor ProteinNOD2 protein, humanNod2 Signaling Adaptor Protein

Autor:innen und Institutionen

  • IrsiCaixa, 08916 Badalona, Barcelona, Spain.
  • Health Research Institute Germans Trias i Pujol (IGTP), Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Barcelona, Spain.
  • University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, CIBERINFEC, 28029 Madrid, Spain.
  • Pulmonology and Allergy Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Barcelona, Spain.

ORCID-Profile: Pere Serra-Mitjà, Ester Ballana

Förderung

  • Instituto de Salud Carlos III
  • Departament de Salut
  • Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS)
  • “Investing in your future”
  • Generalitat de Catalunya and Fons Social Europeu. R.B. and E.B. are research fellows from ISCIII-FIS

Zitieren

APA

Garcia-Vidal, E., Calba, I., Riveira-Muñoz, E., García, E., Clotet, B., Serra-Mitjà, P., Cabrera, C., Ballana, E., & Badia, R. (2024). Nucleotide-Binding Oligomerization Domain 1 (NOD1) Agonists Prevent SARS-CoV-2 Infection in Human Lung Epithelial Cells through Harnessing the Innate Immune Response. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105318

Vancouver

Garcia-Vidal E, Calba I, Riveira-Muñoz E, García E, Clotet B, Serra-Mitjà P, et al. Nucleotide-Binding Oligomerization Domain 1 (NOD1) Agonists Prevent SARS-CoV-2 Infection in Human Lung Epithelial Cells through Harnessing the Innate Immune Response. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105318

BibTeX
@article{GarciaVidal2024,
  author = {Garcia-Vidal, Edurne and Calba, Ignasi and Riveira-Muñoz, Eva and García, Elisabet and Clotet, Bonaventura and Serra-Mitjà, Pere and Cabrera, Cecilia and Ballana, Ester and Badia, Roger},
  title = {Nucleotide-Binding Oligomerization Domain 1 (NOD1) Agonists Prevent SARS-CoV-2 Infection in Human Lung Epithelial Cells through Harnessing the Innate Immune Response},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25105318}
}
Kostenlos starten →